Inflammatory Bowel Disease Market Research
What is Inflammatory Bowel Disease?
Inflammatory bowel disease (IBD) is caused by chronic inflammation of the gastrointestinal (GI) tract and manifests through two conditions: Crohn’s disease and ulcerative colitis (UC). Crohn’s disease occurs when the tissues of the digestive tract swell, causing symptoms such as severe diarrhea, fatigue, abdominal pain, loss of appetite, cramping, and more. UC occurs when the digestive tract becomes inflamed and ulcers form. Symptoms of UC resemble Crohn’s disease, such as abdominal pain, cramping, loss of appetite, diarrhea and fatigue, but may also include symptoms such as bloody stool and rectal bleeding. The major distinction between Crohn’s disease and UC is the parts of the GI tract each disease impacts; Crohn’s disease can affect any part of the tract while UC affects the large intestine. Left untreated, IBD can be life-threatening and may begin to impact other parts of the body besides the GI tract. Treatment can include medication such as antibiotics, steroids, topic medications and immunosuppressants. In some cases, surgery may be recommended to repair blockages, abscesses, and fistulas, or to remove parts of the intestine that have been severely damaged by the disease.
Spherix Global Insights – Gastroenterology – Inflammatory Bowel Disease
Spherix Global Insights’ Gastroenterology therapeutic team is a leading provider of independent Inflammatory bowel disease market research, insights, business intelligence & advisory services.
On an annual basis, Spherix’s Gastroenterology team publishes twelve (12) studies covering IBD including:
- RealTime Dynamix™: Crohn’s Disease (US)
- RealTime Dynamix™: Crohn’s Disease (EU5)
- RealTime Dynamix™: Ulcerative Colitis (US)
- RealTime Dynamix™: Ulcerative Colitis (EU5)
- Launch Dynamix™: Rinvoq (AbbVie) in Ulcerative Colitis (US)
- Launch Dynamix™: Skyrizi (AbbVie) in Crohn’s Disease (US)
- Launch Dynamix™: Etrasimod (Arena) in Ulcerative Colitis (US)*
- Launch Dynamix™: Mirikizumab (Eli Lilly) in Ulcerative Colitis (US)*
- Launch Dynamix™: Rinvoq (AbbVie) in Crohn’s Disease (US)*
- Patient Chart Dynamix™: Biologic/Small Molecule New Starts in IBD (US)
- Patient Chart Dynamix™: Biologic/Small Molecule Switching in IBD (US)
- Patient Chart Dynamix™: Biologic/Small Molecule Switching in IBD (EU5)
*pending approvals and launch
Spherix’s RealTime Dynamix™ service includes quarterly or semiannual reports, respectively in the US and EU, providing an unbiased view of the competitive landscape within the IBD market.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports covering promotional activity, barriers to uptake, and patient types being identified for the launch brand.
Spherix’s Patient Chart Dynamix™ service includes patient level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale patient chart audits.
Follow Spherix Gastroenterology on Social Media
Follow us for gastroenterology industry news, insights & analysis:
Twitter: https://twitter.com/SpherixGastro
LinkedIn: https://www.linkedin.com/company/spherix-global-insights/
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:
